Market Trends of Frontotemporal Disorders Treatment Industry
This section covers the major market trends shaping the Frontotemporal Disorders Treatment Market according to our research experts:
Antidepressants Segment is Expected to Witness Growth Over the Forecast Period
- The antidepressants help to give relief from the symptoms of depression. It is also used to treat anxiety, social and seasonal affective disorders. These drugs generally correct chemical imbalances of neurotransmitters in the brain and are responsible for changing behavior and mood swings. There are different types of antidepressants, such as citalopram (Celexa), escitalopram (Lexapro), fluvoxamine (Luvox), fluoxetine (Prozac, Sarafem), sertraline (Zoloft), and paroxetine (Paxil).
- Most antidepressants belong to these groups, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants. However, antidepressants have certain side effects, such as weight gain, sleepiness, diarrhea, nausea & vomiting, and sexual problems.
- The increasing cases of anxiety, dementia, depression, and Alzheimer's dementia is the major driver for the segment's growth. For instance, as per the report published by the Vietnam Country Policy in May 2021, the most common types of mental health problems among children of Vietnam are anxiety, loneliness, and depression. It also reported that most studies indicate children are more susceptible to depression than adults. Similarly, as per the report published by NCBI in April 2022, the majority of individuals with depression experience sleep disturbances. It also reported that depression is also overrepresented among populations with various sleep disorders.
- Although sleep disturbances are typical features of depression, these symptoms sometimes appear before an episode of depression. Therefore, this may increase the demand for antidepressant drugs as it is generally used to treat depression and related symptoms such as insomnia, dementia, and stress, thereby propelling the segment growth during the forecast period.
- The increasing research work and product launches by the key players are also anticipated to boost segment growth. For instance, in March 2022, Sun Pharma entered into an exclusive patent licensing agreement with Danish drugmaker Lundbeck to market and distribute its version of antidepressant medication Vortioxetine in India under the brand name Vortidiftm. Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat the major depressive disorder (MDD) in adults. The product is approved in over 80 countries, including the US, EU, Canada, and Australia. Therefore, such positive developments are expected to propel the segment's growth.
- Therefore, significant segment growth is expected during the forecast period owing to the above-mentioned factors.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Witness Growth Over the Forecast Period
- North America is expected to dominate the overall frontotemporal disorders treatment market during the forecast period. The growth is due to increasing cases of dementia, anxiety, and frontotemporal disorders, the rising geriatric population, and increasing research work related to frontotemporal disorders treatment.
- For instance, according to the report published by the Alzheimer's and Dementia Organization Canada in January 2022, around 569,600 Canadians were living with dementia in 2020, and around 747,000 Canadians will be living with Alzheimer's or another dementia in 2022. The report also stated that around 124,000 Canadians were diagnosed with dementia in 2020, and around 955,900 Canadians are expected to live with dementia by 2030. Therefore, such instances are anticipated to propel market growth in the North American region.
- Key product launches, product approval, high concentration of market players or manufacturer's presence, acquisition and partnerships among major players, and increasing cases of dementia and frontotemporal disorders in the United States are some of the factors driving the growth of the frontotemporal disorders treatment market in the country.
- For instance, in December 2021, the US FDA approved Caplyta (lumateperone) for treating bipolar depression in adults. Caplyta, an atypical antipsychotic from the biopharmaceutical company Intra-Cellular Therapies, is the only drug approved by the FDA for the treatment of depressive episodes stemming from bipolar I or bipolar II disorder in adults as monotherapy or adjunctive therapy with either valproate or lithium.
- Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the North America Region.
Get Analysis on Important Geographic Markets
Download PDF
